Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy

JAMA

Volumn 278, Issue 24, 1997, Pages 2170-2177

  Nowell, Peter D ^a,b   Mazumdar, Sati ^b   Buysse, Daniel J ^a   Dew, Mary Amanda ^a   Reynolds III, Charles F ^a   Kupfer, David J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ZOLPIDEM;

DRUG EFFICACY; HUMAN; INSOMNIA; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REVIEW; SLEEP; TREATMENT OUTCOME;

EID: 0031469929     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.24.2170     Document Type: Review

References (86)

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates Arch Gen Psychiatry. 1985;42:225-232.
2. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry. 1992;53(suppl):34-39.
3. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16:873-97. Review Discussion 854.
4. Walsh JK, Engelhardt CL, Hartman PG. The direct economic cost of insomnia. In: Hypnotics and Anxiolytics: Bailliere's Clinical Psychiatry. London, England: Bailliere Tindall; 1995.
5. Kales A, Caldwell AB, Soldates CR, Bixler EO, Kales JD. Biopsychobehavioral correlates of insomnia, II: pattern specificity and consistency with the Minnesota Multiphasic personality inventory. Psychosom Med. 1983;45:341-356.
6. Tan TL, Kales JD, Kales A, Soldatos CR, Bixler EO. Biopsychobehavioral correlates of insomnia, IV: diagnosis based on DSM-III. Am J Psychiatry 1984;141:357-362.
7. Schramm E, Hohagen F, Kappler C, Grasshoff U, Berger M. Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr Scand. 1995;91:10-17.
8. Gislason T, Almqvist M. Somatic diseases and sleep complaints: an epidemiological study of 3201 Swedish men. Acta Med Scand. 1987;221:475-481.
9. Vollrath M, Wicki W, Angst J. The Zurich Study, VIII, insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia. Eur Arch Psychiatry Clin Neurosci. 1989;239:113-124.
10. Whorwell PJ, McCallum M, Creed FH. Noncoloni cfeatures of irritable bowel syndrome. Gut. 1986; 27:37-40.
11. Johnson LC, Spinweber CL. Good and poor sleepers differ in Navy performance. Mil Med. 1983; 148:727-731.
12. Mendelson WB, Garnett D, Linnoila M. Do insomniacs have impaired daytime functioning? Biol Psychiatry. 1984;19:1261-1264.
13. Mendelson WB, Garnett D, Gillin JC, Weingartner H. The experience of insomnia and daytime and nighttime functioning. Psychiatry Res. 1984;12:235-250.
14. Sugarman JS, Stern JA, Walsh JK. Daytime alertness in subjective and objective insomnia: some preliminary findings. Biol Psychiatry. 1985;20: 741-750.
15. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. JAMA. 1989;262:1479-1484.
16. Angst J, Vollrath M, Koch R, Dobler-Mikola A. The Zurich Study, VII: insomnia: symptoms, classification and prevalence. Eur Arch Psychiatry Clin Neurosci. 1989;238:285-293.
17. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: the movies project. J Am Geriatr Soc. 1996;44:778-784.
18. Mendelson WB. Long-term follow-up of chronic insomnia. Sleep. 1995;18:698-701.
19. Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry. 1992;53 (suppl):37-41.
20. Hauri P. Treating psychophysiologic insomnia with biofeedback. Arch Gen Psychiatry. 1981;38: 752-758.
21. Hauri P, Fisher J. Persistent psychophysiologic (learned) insomnia. Sleep. 1986;9:38-53.
22. Morin CM, Colecchi CA, Stone J, Sood RK, Brink D. Cognitive-behavior therapy and pharmacotherapy for insomnia: update of a placebo-controlled clinical trial. Sleep Res. 1995;24:303.
23. Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med. 1997;336:341-346.
24. Bliwise DL. Treating insomnia: pharmacological and nonpharmacological approaches. J Psychoactive Drugs. 1991;23:335-341.
25. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology. 1995;118:107-15. Review Discussion 118.
26. Linsen SM, Zitman FG, Breteler MH. Defining benzodiazepine dependence: the confusion persists. European Psychiatry. 1995;10:306-311.
27. Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry. 1992;53(suppl):10-7. Discussion 18.
28. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry. 1983;44:25-28.
29. Lilie JK, Lahmeyer H. Psychiatric management of sleep disorders. Psychiatric Medicine. 1991;9:245-260.
30. Pearce PL. Trends in pharmacologic treatment of insomnia. J Clin Psychiatry. 1994;55:163-164.
31. Staedt J, Stoppe G, Hajak G, Mullerstruck A, Ruther E. Chronic insomnia: what should be done if minor tranzuilizers are no longer helpful? Fortschr Neurol Psychiatr. 1995;63:368-372.
32. National Institute of Mental Health. Consensus conference report: drugs and insomnia - the use of medication to promote sleep. JAMA. 1984;251:2410-2414.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:551-607.
34. Diagnostic Classification Steering Committee T. International Classification of Sleep Disorders: Diagnostic and Coding Manual. Rochester, Minn: American Sleep Disorders Association; 1990:27-38.
35. World Health Organization. Mental Disorders: Glossary and Guide to Their Classification in Accordance With the 9th Revision of the International Classification of Diseases. Geneva, Switzerland: World Health Organization; 1978.
36. Kripke DF, Hauri P, Ancoli-Israel S, Roth T. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 1990;10(suppl):32S-43S.
37. Hajak G, Clarenbach P, Fischer W, Haase W, Ruther E. Zopiclone improves sleep quality and day-time well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol. 1994;9:251-261.
38. Akerstedt T, Hume K, Minors D, Waterhouse J. The subjective meaning of good sleep, an intraindividual approach using the Karolinska Sleep Diary. Percept Mot Skills. 1994;79:287-296.
39. Carskadon M, Dement W, Mitler M, Guilleminault C, Zarcone V, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry. 1976;133:1382-1388.
40. Hunter JE, Schmidt FL, Jackson GB. Metaanalysis: Cumulating Research Findings Across Studies. Beverly Hills, Calif: Sage; 1982:12-34.
41. Rosenthal R. Meta-analytic Procedure for Social Research. Beverly Hills, Calif: Sage; 1984:93-216.
42. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172-1180.
43. Murtagh DRR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63:79-89.
44. Buysse DJ, Reynolds CF, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using ICSD, and proposed DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV field trials. Sleep. 1994;17:630-637.
45. Buysse DJ, Reynolds CF, Kupfer DJ, Mesiano D. Does diagnosis affect treatment recommendations in insomnia patients? Sleep Res. 1993;22:178.
46. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18: 246-251.
47. Frankel BL, Coursey RD, Buchbinder R, Snyder F. Recorded and reported sleep in chronic primary insomnia. Arch Gen Psychiatry. 1976;33: 615-623.
48. Roehrs T, Vogel G, Vogel F, et al. Eligibility requirements in hypnotic trials. Sleep. 1985;8:34-39.
49. Steinmark SW, Borkovec TD. Active and placebo treatment effects on moderate insomnia under counterdemand and positive demand instructions. J Abnorm Psychol. 1974;83:157-163.
50. Carr-Kaffashan L, Woolfolk RL. Active and placebo effects in treatment of moderate and severe insomnia. J Consult Clin Psychol. 1979;47:1072-1080.
51. Borkovec TD. Insomnia. J Consult Clin Psychol. 1982;50:890-895.
52. Reynolds CF, Nowell PD, Hoch CC, Neylan TC, Buysse DJ, Kupfer DJ. Diagnosis and treatment of insomnia in the elderly. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. Baltimore, Md: Williams & Wilkins. In press.
53. Hoch CC, Dew MA, Reynolds CF, et al. Longitudinal changes in diary-and laboratory-based sleep measures in health 'old old' and 'young old' subjects: a 3-year follow-up. Sleep. 1997;20:192-202.
54. Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry. 1992;53(suppl):7-13.
55. Bangert-Drowns RL. Review of developments in meta-analytic method. Psychol Bull. 1986;99:388-399.
56. Rosenthal R, Rubin DB. Meta-analytic procedures for combining studies with multiple effect sizes. Psychol Bull. 1986;99:400-406.
57. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1977.
58. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press; 1985.
59. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York, NY: Oxford University Press; 1994:119-123.
60. Aden GC, Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry. 1983;44:454-456.
61. Cohn JB, Wilcox CS, Bremner J, Ettinger M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31:747-750.
62. Cohn JB. Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. J Clin Psychiatry. 1984;45:104-107.
63. Cuanang JR, Limos L. Treatment of insomnia with temazepam: double-blind, placebo-controlled evaluation. Clin Ther. 1982;4:402-412.
64. Declerck AC, Ruwe F, O'Hanlon JF, Vermeeren A, Wauquier A. Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia. Psychopharmacology. 1992;106:497-501. Correction: Psychopharmacology. 1992;109:254.
65. Melo de Paula AJ. Comparative study of lormetazepam and flurazepam in the treatment of insomnia. Clin Ther. 1984;6:500-508.
66. Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. Comparative efficacy of estazolam, flurazepam, and placebo in outpatients with insomnia. J Clin Psychiatry. 1986;47:362-365.
67. Elie R, Lavoie G, Bourgouin J, Le Morvan P. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol. 1990;5:279-286.
68. Fabre LF Jr, Brachfeld J, Meyer LR, Slowe IA, Calvo R, Metzler C. Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia. J Clin Psychiatry. 1978;39:679-682.
69. Fillingim JM. Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia. Br J Clin Pharmacol. 1979;8(suppl):73S-77S.
70. Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic learned insomnia: psychometric and polysomnographic evaluation. J Int Med Res. 1993; 21:306-322.
71. Hernandez-Lara R, Del Rosal PL, Ponce MC. Short-term study of quazepam 15 milligrams in the treatment of insomnia. J Int Med Res. 1983;11:162-166.
72. Linnoila M, Viukari M, Lamminsivu U, Auvinen J. Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric inpatients. Int Pharmacopsychiatry. 1980;15:129-135.
73. Mendels J, Stern S. Evaluation of the short-term treatment of insomnia in out-patients with 15 milligramsof quazepam. J Int Med Res. 1983;11:155-161.
74. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 1994;27:166-175.
75. Nair NP, Schwartz G, Dimitri R, Le Morvan P, Thavundayil JX. A dose range finding study of zopiclone in insomniac patients. Int Clin Psychopharmacol. 1990;52(suppl):1-10.
76. Ponciano E, Freitas F, Camara J, Faria M, Barreto M, Hindmarch I. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol. 1990;52(suppl):69-77.
77. Scharf MB, Roth PB, Dominguez RA, Ware JC. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30:461-467.
78. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199.
79. Walsh JK, Targum SD, Pegram V, et al. A multicenter clinical investigation of estazolam: short-term efficacy. Curr Ther Res. 1984;36:866-874.
80. Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL, Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol. 1987;27:508-515.
81. Kales A, Soldatos CR, Bixler EO, Kales JD, Vela-Bueno A. Diazepam: effects on sleep and withdrawal phenomena. J Clin Psychopharmacol. 1988; 8:340-346.
82. Mitler MM, Seidel WF, Van Den Hoed J, Greenblatt DJ, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol. 1984;4:2-13.
83. Hauri PJ. Sleep hygiene, relaxation therapy, and cognitive interventions. In: Hauri PJ, ed. Case Studies in Insomnia. New York, NY: Plenum Publishing Corp; 1991:65-84.
84. Hauri PJ. The Sleep Disorders. Kalamazoo, Mich: The Upjohn Co; 1982:1-32.
85. Morin CM, Colecchi C, Brink D, Astruc M, Mercer J, Remsberg S. How 'blind' are double-blind placebo-controlled trials of benzodiazepine hypnotics? Sleep. 1995;18:240-245.
86. Orwin P. A fail-safe n for effect size in meta-analysis. J Educ Stat. 1983;8:157-159.